Alzheimer’s Disease

Phase I clinical trial of drug was successfully completed at the Warren Center for Neuroscience Drug Discovery, with promise to treat Alzheimer’s and other neurodegenerative diseases. The compound, named VU319, is the first Vanderbilt end-to-end drug discovery effort related to memory loss, starting from the earliest basic science research through human clinical trials. Read More

Olivia Kelly, a Ph.D. student in the Heidi Hamm lab, received an award to study non-drug-based interventions for maintaining or restoring wellness to prevent Alzheimer’s disease. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

The Warren Center for Neuroscience Drug Discovery opened its doors to the Nashville community to share firsthand the pioneering work it is conducting on Alzheimer’s disease, Parkinson’s disease, addiction, and more. Read More

The Vanderbilt Memory and Alzheimer's Center hosted its fifth Annual Vanderbilt Alzheimer’s Disease Research Day on April 10 with the theme of “big data.” Aside from presentations from faculty from across campus and the School of Medicine Basic Sciences, the day featured data blitzes, a keynote presentation, and a poster reception with more than 45 posters. Read More

Cohen was awarded the 1986 Nobel Prize in Physiology or Medicine for his discovery of epidermal growth factor, a protein produced in the body that influences the development of nerve and skin tissues by stimulating cell growth and differentiation. The discovery of EGF launched an entire field of research into growth factor signaling and had major impacts on human health. Read More

The team prompted the chatbot to review the biomedical research literature and suggest 20 drugs for Alzheimer’s disease, ranking them for potential effectiveness. With a second prompt they asked for confirmation of the initial 20 suggestions. They repeated both prompts 10 times. Read More